Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > ACADEMIA
ACADEMIA
- The Lancet Announces Retraction of JIKEI Paper on Diovan Trial, Says There’s “Sufficient Doubt”
September 9, 2013
- Tokushukai Group to Cancel Use of Diovan Products at Its 66 Hospitals
August 28, 2013
- Go-Between Faculty Member for Ex-Employee and Osaka City University Received 4 Million Yen in Grants from Novartis
August 26, 2013
- Osaka City University Slams Lead Investigators of Diovan Trials; They “Knew of His Novartis Affiliation”
August 26, 2013
- JSMO Announces Guidance on Prevention and Treatment of Tumor Lysis Syndrome; Rasburicase Recommended for High-risk Patients
August 22, 2013
- Health Ministry’s Diovan Committee Should Question Bosses of Ex-Novartis Employee Too, Says Key Member
August 19, 2013
- JASDI Conducting Survey on Inconsistencies in Package Inserts of Similar Drugs; Will Come Up with Improvement Proposal by Year-End
August 19, 2013
- JSGM Initiates Plan to Unify Brand Names of Generic Fixed-dose Combination Drugs to Prevent Medication Errors
August 19, 2013
- St. Marianna University School of Medicine Hospital Ends Use of Diovan for Patients
August 16, 2013
- British Journal The Lancet Begins Process of Retracting JIKEI Heart Study
August 16, 2013
- Japan Hypertension Society Sets Up Ethics Committee amid Diovan Fuss
August 8, 2013
- Japan Hypertension Society Deletes Citations of JIKEI Study from Treatment Guidelines
August 8, 2013
- NCC Sets Sights on World’s Top Development Hub with New Exploratory Clinical Research Center
August 7, 2013
- Draft of Hypertension Guidelines Recommends CCBs, ARBs, ACE Inhibitors, and Diuretics as First-Line Drugs, Excludes Beta Blockers
August 6, 2013
- The Lancet Has Not Received Notification from Jikei University on Investigation Findings: Spokesperson
August 1, 2013
- Ex-Novartis Employee Manipulated Blood Pressure Data in JIKEI Study: Univ. Probe
July 31, 2013
- Role of Companies in Clinical Research Discussed at JAPhMed Annual Meeting
July 24, 2013
- University’s Seriousness to Unravel Diovan Saga Called into Question
July 17, 2013
- Univ. Fails to Question Ex-Novartis Employee over KYOTO Study, Says Internal Probe “Has Limitations”
July 16, 2013
- “Data Manipulated” in KYOTO Heart Study: Univ. Probe
July 12, 2013
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…